@FiercePharma: Japan's Astellas splashes out $300M for Immunomic's LAMP-vax platform. FiercePharmaAsia story | Follow @FiercePharma
@EricPFierce: ICYMI: Sanofi's Kansas City, MO plant back on the block as its August 2016 closing looms. Story | Follow @EricPFierce
@CarlyHFierce: J&J plots $10B buyback as plummeting hep C sales tarnish Q3. Article | Follow @CarlyHFierce
> Merck ($MRK) and Incyte ($INCY) have expanded their clinical trial collaboration to include a Phase III study combining Merck's Keytruda with Incyte's epacadostat as a first-line treatment for advanced melanoma. Release
> Mylan ($MYL) says it has no obligation to publish a prospectus in Israel for its takeover bid just because Perrigo ($PRGO) is listed on the country's stock exchange. Report
> Helsinn Healthcare and Dr. Reddy's Laboratories ($RDY) have entered into a settlement to resolve a patent fight over Helsinn's Aloxi injection in the U.S., where it is distributed by Eisai. Release
> The Drug Enforcement Agency's (DEA) attempts at stemming painkiller abuse is falling short at pharmacies. More (sub. req.)
> Chinese hospitals have reported shortages of some cheap but essential medicines thanks to alleged monopolies on raw materials. Report
> Japan's Otsuka Pharmaceutical has lost its bid for attorney fees in an Abilify patent dispute. More (reg. req.)
Medical Device News
@FierceMedDev: ICYMI yesterday: Clinicians criticize Baxter for suspending comparative drug/device heart failure trial. Article | Follow @FierceMedDev
@VarunSaxena2: Clinicians criticize Baxter for suspending comparative drug/device heart failure trial. More | Follow @VarunSaxena2
@EmilyWFierce: Report: AstraZeneca funnels billions into Dutch tax-avoidance scheme. FiercePharma story | Follow @EmilyWFierce
> Is Turing illegally thwarting generic copycats? New York antitrust squad wants to know. More
> J&J plots $10B buyback as plummeting hep C sales tarnish Q3. Article
Biotech News
@FierceBiotech: 5 experts, 1 voice: Biotech bubble? It's different this time. Editor's corner | Follow @FierceBiotech
@JohnCFierce: Analysts, experts write off Merck's huge anacetrapib PhIII. Report | Follow @JohnCFierce
@DamianFierce: Entirely baffled by $XON's business model. More | Follow @DamianFierce
> Zafgen shares continue to slide on market fears. Item
> Protalix flips its Gaucher drug to Pfizer for $46M in R&D cash. Report
> FDA misses approval date for Collegium's pain drug. News
Drug Delivery News
> Study finds EpiPens can injure children, recommends improved technique and design. More
> Russian Academy: Combining drugs with ionic liquids can up the solubility, cut polymorphism. News
> Medicines Co. enters Japanese market, handing over license to transdermal pain patch. Story
> OptiNose bags $30M in VC financing as partner Otsuka barrels toward its second PDUFA date. Article
> 3M takes on blood-brain barrier with Impel Neuropharma nasal drug delivery alliance. Report
Pharma Manufacturing News
> Pests again figure into issues in FDA warning letter to Indian API maker. More
> Cipla's new U.S. plant received Form 483 just ahead of deal. News
> CPhI report predicts growth in outsourcing for sterile injectables. More
> Aurobindo to expand India API plant fourfold. Story
> Hong Kong's gray market draws mainland Chinese looking for lifesaving meds they can't afford at home. Article
Pharma Asia News
> HK-listed 3SBio inks oncology antibody drug deal with South Korea's Alteogen. Story
> CIMB says Malaysian pharmas have scope to adjust to TPP changes. Report
> China's Innovent Biologics deepens pact with Eli Lilly on immuno-oncology. Article
> Japan's Astellas splashes out $300M for Immunomic's LAMP-vax platform. Item
> Hong Kong drugstores attract Chinese customers for cancer, hep C drugs. More
And Finally... Health officials and healthcare execs working to combat the rise in drug-resistant infections are training their eyes on nursing homes, where antibiotics are among the most frequently prescribed meds. More (sub. req.)